Neuland Labs Strengthens Board with Pharma Veteran Dr. Ravi Shankar Gopinath as Independent Director

Hyderabad, India – Neuland Laboratories Ltd., a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates, has announced a significant bolstering of its Board of Directors with the appointment of Dr. Ravi Shankar Gopinath as an Independent Director. This strategic move, effective from August 1, 2024, for a term of five years, is poised to bring unparalleled expertise and a fresh strategic perspective to the company.

Dr.

Ravi Shankar Gopinath is a highly respected figure in the global pharmaceutical landscape, boasting an impressive career spanning over three decades. His extensive experience encompasses critical areas such as Research & Development, Manufacturing, Quality Assurance, and Supply Chain management, making him an invaluable asset to Neuland Labs.

Academically, Dr.

Gopinath holds a Ph.D. in Organic Chemistry from the prestigious Ohio State University, followed by significant postdoctoral research at Harvard University. This strong scientific foundation has underpinned a career marked by leadership and innovation in the pharma sector.

Before his current role as a Strategic Advisor to various pharmaceutical companies, Dr.

Gopinath held several pivotal leadership positions at Dr. Reddy’s Laboratories Ltd. During his tenure, he served as President and Global Head of Formulations Research & Development and Medical Affairs, a role that saw him drive innovation and product development on a global scale. He also headed Dr.

Reddy's APIs and served as the Chief Technology Officer (CTO) for Active Pharmaceutical Ingredients, Biologics, and Chemical businesses, demonstrating his versatile leadership across diverse pharmaceutical domains.

His deep understanding of API development, biologics, and formulations, coupled with his strategic acumen, has been honed through years of leading large, complex global teams.

Dr. Gopinath’s experience extends to corporate governance, having previously served on the board of Aurigene Discovery Technologies Ltd. and currently serving on the board of Cellix Bio Pvt. Ltd.

Neuland Laboratories expressed immense enthusiasm regarding Dr. Gopinath’s appointment. The company anticipates that his profound strategic insights and seasoned leadership will be instrumental in guiding Neuland Labs through its next phase of growth and innovation.

His proven track record of driving success in a highly competitive industry aligns perfectly with Neuland’s commitment to excellence and its vision for future expansion.

This appointment underscores Neuland Laboratories' dedication to strengthening its governance and leveraging top-tier talent to navigate the evolving pharmaceutical landscape.

With Dr. Gopinath on board, Neuland Labs is set to reinforce its position as a key player in the global pharmaceutical market, enhancing its capabilities in API manufacturing and custom synthesis.